[HTML][HTML] An ethnopharmacological review on the therapeutical properties of flavonoids and their mechanisms of actions: A comprehensive review based on up to date …

DH Abou Baker - Toxicology reports, 2022 - Elsevier
Flavonoids-a class of low molecular weight secondary metabolites-are ubiquitous and
cornucopia throughout the plant kingdom. Structurally, the main structure consists of C6-C3 …

The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification

A Rowland, JO Miners, PI Mackenzie - … journal of biochemistry & cell biology, 2013 - Elsevier
Human UDP-glucuronosyltransferase (UGT) exists as a superfamily of 22 proteins, which
are divided into 5 families and 6 subfamilies on the basis of sequence identity. Members of …

Metabolism and disposition kinetics of nicotine

J Hukkanen, P Jacob III, NL Benowitz - Pharmacological reviews, 2005 - Elsevier
Nicotine is of importance as the addictive chemical in tobacco, pharmacotherapy for
smoking cessation, a potential medication for several diseases, and a useful probe drug for …

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients

CE Staatz, SE Tett - Clinical pharmacokinetics, 2007 - Springer
This review aims to provide an extensive overview of the literature on the clinical
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …

Molecular mechanism of phase I and phase II drug‐metabolizing enzymes: implications for detoxification

T Iyanagi - International review of cytology, 2007 - Elsevier
Enzymes that catalyze the biotransformation of drugs and xenobiotics are generally referred
to as drug‐metabolizing e nzymes (DMEs). DMEs can be classified into two main groups …

Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non–Small-Cell Lung Cancer Treated …

JY Han, HS Lim, ES Shin, YK Yoo, YH Park… - Journal of clinical …, 2006 - ascopubs.org
Purpose To determine whether uridine diphosphate-glucuronosyltransferase 1A1, UGT1A7,
and UGT1A9 polymorphisms affect the pharmacokinetics (PK) of irinotecan and treatment …

[HTML][HTML] Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years

M Panczyk - World Journal of Gastroenterology: WJG, 2014 - ncbi.nlm.nih.gov
During the past two decades the first sequencing of the human genome was performed
showing its high degree of inter-individual differentiation, as a result of large international …

UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan

LE Carlini, NJ Meropol, J Bever, ML Andria, T Hill… - Clinical Cancer …, 2005 - AACR
Purpose: Capecitabine and irinotecan are commonly used in the treatment of metastatic
colorectal cancer (CRC). We hypothesized that germline polymorphisms within genes …

Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography–tandem mass …

DE Harbourt, JK Fallon, S Ito, T Baba, JK Ritter… - Analytical …, 2012 - ACS Publications
Uridine-disphosphate glucuronosyl transferase (UGT) enzymes catalyze the formation of
glucuronide conjugates of phase II metabolism. Methods for absolute quantification of …

Pharmacogenetics of irinotecan metabolism and transport: an update

NF Smith, WD Figg, A Sparreboom - Toxicology in vitro, 2006 - Elsevier
The anticancer agent irinotecan (CPT-11) is converted to SN-38, which is approximately 100
to 1000-fold more cytotoxic than the parent drug. The pharmacokinetics of irinotecan are …